title: Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. Danish-Swedish Multicenter Study Group.
abstract: BACKGROUND
  In southern Scandinavia most babies with respiratory distress syndrome are initially treated with nasal continuous positive airway pressure. We performed a multicenter trial to investigate whether the addition of a single dose of porcine surfactant administered during a short intubation before the occurrence of serious deterioration could reduce the subsequent need for mechanical ventilation.
  
  
  METHODS
  We randomly assigned 35 infants with moderate-to-severe respiratory distress syndrome to surfactant therapy (Curosurf, 200 mg per kilogram of body weight) plus nasal continuous positive airway pressure and 33 infants to nasal continuous positive airway pressure alone. The study was not blinded. The indications for mechanical ventilation were a ratio of arterial to alveolar oxygen tension of less than 0.15, severe apneic attacks, or both.
  
  
  RESULTS
  Six hours after randomization, when the median age of the babies was 18 hours, the mean ratio of arterial to alveolar oxygen tension was 0.37 in the surfactant-treated babies, as compared with 0.25 in the controls (P < 0.001). The need for subsequent mechanical ventilation was reduced with surfactant therapy (to 43 percent of the surfactant-treated babies as compared with 85 percent of the controls; P = 0.003). When 17 infants with ratios of arterial-to-alveolar oxygen tension of less than 0.15 at randomization were excluded, the need for mechanical ventilation was still significantly reduced in the surfactant-treated group (to 33 percent [9 of 27 babies], as compared with 83 percent [20 of 24 babies] in the control group; (P < 0.001). After 28 days, two of the surfactant-treated babies had died, as compared with five of the control babies.
  
  
  CONCLUSIONS
  In babies with moderate-to-severe respiratory distress syndrome treated with nasal continuous positive airway pressure, a single dose of surfactant reduced the need for subsequent mechanical ventilation.
authors.affiliation: Department of Pediatrics, Holbaek Central Hospital, Denmark.
authors.forename: H
authors.initials: H
authors.lastname: Verder
authors.forename: B
authors.initials: B
authors.lastname: Robertson
authors.forename: G
authors.initials: G
authors.lastname: Greisen
authors.forename: F
authors.initials: F
authors.lastname: Ebbesen
authors.forename: P
authors.initials: P
authors.lastname: Albertsen
authors.forename: K
authors.initials: K
authors.lastname: Lundstrøm
authors.forename: T
authors.initials: T
authors.lastname: Jacobsen
mesh_terms: D001688:Biological Products; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007440:Intubation; D008297:Male; D009666:Nose; D010100:Oxygen / Q000502:physiology; D010743:Phospholipids; D011175:Positive-Pressure Respiration; D011663:Pulmonary Surfactants / Q000008:administration & dosage / Q000627:therapeutic use*; D012044:Regression Analysis; D012127:Respiratory Distress Syndrome, Newborn / Q000503:physiopathology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D001688:Biological Products; D010743:Phospholipids; D011663:Pulmonary Surfactants; C068291:poractant alfa; D010100:Oxygen